Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the period from March 27, 2026, to May 22, 2026, with the report issued on May 26, 2026. The filing serves as a notification to the market regarding the admission of additional ordinary shares to trading on the London Stock Exchange Main Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share admissions and does not contain financial performance data.
Material Changes
The material change reported is the admission of 45,273 additional ordinary shares of 31½ pence each to trading. These shares are associated with the "GlaxoSmithKline plc Share Save Plan 2022" and are fully fungible with existing ordinary shares. Following this admission, the total number of securities admitted to trading stands at 4,316,221,551.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the mechanics of the share admission.
Investor Verification Checklist
- Verify the total number of outstanding ordinary shares (4,316,221,551) against the company's latest annual report.
- Confirm the ISIN code (GB00BN7SWP63) for the ordinary shares of 31½ pence each.
- Review the terms of the "GlaxoSmithKline plc Share Save Plan 2022" to understand the source of the newly admitted shares.
- Check the London Stock Exchange Main Market listing status for GSK plc.